公开(公告)号：US11327078B2

公开(公告)日：2022-05-10

申请号：US16965161

申请日：2019-02-25

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Yoko Ida ,  Takashi Obara ,  Emiko Yumoto

IPC: G01N33/577 ,  C07K16/18

Abstract: The present invention provides an anti-APOA4 monoclonal antibody or an antibody fragment thereof capable of accurately measuring apolipoprotein A-IV (APOA4) in a specimen, a measurement method for immunologically measuring APOA4 using the antibody or the antibody fragment thereof, and a kit for measuring APOA4 containing the antibody or the antibody fragment thereof.

公开(公告)号：US20200341014A1

公开(公告)日：2020-10-29

申请号：US16078557

申请日：2017-03-16

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Mai Kimura ,  Sotaro Motoi ,  Takashi Obara ,  Katsuhiro Moriya ,  Hideaki Ogasawara ,  Yoshihisa Arita ,  Tetsu Kawano

IPC: G01N33/92 ,  C12Q1/6883

Abstract: The present invention provides a method for evaluating the pharmacological action of HGF that utilizes a PD marker in which fluctuation is recognized by administration of hepatocyte growth factor (HGF) in a broader range of subjects. A method for evaluating the pharmacodynamic action of HGF is provided. The aforementioned evaluation method is characterized in that it comprises a step of measuring the ApoA4 level in a biological sample collected from a test subject who was administered HGF. According to the present invention, a kit for evaluating the pharmacodynamic action of HGF comprising an anti-ApoA4 antibody is further provided.